Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179331 | 0.86 | CTSK (0.44) | CTSK | |
| SCHEMBL4185708 | 0.82 | LMNA (0.50) | MAPK1KMT2AMEN1LMNAHDAC1 | |
| SCHEMBL7743269 | 0.77 | CTSK (0.43) | CTSKALDH1A1 | |
| SCHEMBL31477252 | 0.77 | CTSK (0.43) | KMT2AMEN1CTSKALDH1A1 | |
| SCHEMBL7750570 | 0.77 | CTSK (0.43) | CTSKALDH1A1 | |
| SCHEMBL7747431 | 0.76 | CTSK (0.42) | CTSKALDH1A1 | |
| SCHEMBL31477520 | 0.75 | KMT2A (0.42) | KMT2AMEN1LMNABTN3A1ALDH1A1 | |
| SCHEMBL4186450 | 0.74 | HTT (0.56) | HTTMAPK1KMT2AKEAP1NFE2L2 | |
| SCHEMBL5839863 | 0.73 | CYP2D6 (0.39) | MAPK1KMT2AMEN1LMNA | |
| SCHEMBL3780925 | 0.72 | CTSK (0.43) | CTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | HTT 2412/4885MAPK1 1653/4885KMT2A 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.